-+ 0.00%
-+ 0.00%
-+ 0.00%

Sanofi (ENXTPA:SAN) Wins FDA Approval, Is The Valuation Already Too Rich?

Simply Wall St·11/19/2026 10:11:54
Listen to the news

Sanofi (ENXTPA:SAN) just received US FDA approval for Infilbray, an oral treatment for neurological symptoms of Type 3 Gaucher disease. This kind of new therapy decision can reshape how investors think about the business.

Set against a one month share price return of 21.46% and a 90 day gain of 10.88%, the latest move to €86.25 suggests Sanofi’s momentum has been picking up recently. A 1 year total shareholder return of 5.97% points to steadier, slower progress over a longer stretch.

See how Sanofi’s approval-led momentum compares with other healthcare groups by filtering for 124 healthcare AI stocks that could be shaping the next wave of data-driven drug development.

Bulls see the Infilbray approval and €86.25 share price as a springboard. Bears point to execution risk and drug specific safety flags. Which case does Sanofi’s current valuation lean toward?

Most Popular Narrative: 19% Overvalued

Against Sanofi’s last close at €86.25, the most followed narrative on Simply Wall St puts fair value at €72.23, which implies a valuation gap that some investors see as meaningful. According to Szock, an investor in the Simply Wall St Community who wrote the narrative, that gap sits at the crossroads of income appeal and business resilience.

Der französische Pharmariese Sanofi bietet Anlegern derzeit eine interessante Kombination aus attraktiver Bewertung, starker Dividendenrendite und solider operativer Dynamik.​ Attraktive Bewertung und Kursrücksetzer: Die Aktie hat in den vergangenen Monaten nachgegeben und bewegt sich im Bereich von rund 76 bis 77 EUR. Damit notiert sie deutlich unter ihren früheren Höchstständen. Für langfristig orientierte Investoren eröffnet dieser Rücksetzer einen günstigen Einstiegspunkt, da das Kurs-Gewinn-Verhältnis (KGV) auf Basis der erwarteten Gewinne moderat ist und Analysten den fairen Wert spürbar höher ansetzen.

See why 6 investors see Sanofi as 19% overvalued.

Result: Fair Value of €72.23 (OVERVALUED)

Still, Sanofi’s story can break if key drugs face tougher regulation or if the Consumer Health separation introduces higher costs and operational friction than bulls expect.

Find out about the key risks to this Sanofi narrative.

Another View: Sanofi Through A Cash Flow Lens

The community narrative tags Sanofi as 19% overvalued at €72.23, yet the SWS DCF model points in a very different direction. On that framework, the projected future cash flows suggest a value of €266.72 per share, which would place the current €86.25 level far below that estimate. It raises a simple question: Are earnings based ratios missing part of the story here?

For readers who want to see how that projection is built step by step, Look into how the SWS DCF model arrives at its fair value.

SAN Discounted Cash Flow as at Nov 2026
SAN Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sanofi for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 209 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Does the split view on Sanofi’s value leave you unsure which side to back right now? Look through the data, weigh the trade off between the risks that concern investors and the potential rewards they are watching, then ground your stance in the 2 key rewards and 3 important warning signs.

Looking for more Sanofi style investment ideas?

If Sanofi’s split valuation views have you thinking about diversification, use that curiosity as a push to scan wider, compare different business profiles, and build a watchlist that really fits your risk and income goals.